Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Novartis AG/Chinook Therapeutics, Inc. merger agreement
| June 11, 2023 • Antitrust Risk-shifting • $3.2 billion (or $3.5 billion, including contingent value right payments). |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.